Research Leaders / KOL Map

Breast Cancer: Research Leaders and Landscape

The most active researchers, institutions, and subtopics in Breast Cancer, from recent PubMed records. Public authorship only, every figure verifiable by PMID.

Analyzed 597 recent PubMed papers (2021-2026) matching "breast cancer HER2 antibody drug conjugate". Source: NLM PubMed. Generated July 2026.

Top research leaders (by recent publication volume)

#ResearcherAffiliationPapers
1Im Seock-AhSeoul National University Hospital15
2Cortés JavierInternational Breast Cancer Center15
3Park Yeon HeeSungkyunkwan University School of Medicine13
4Bardia AdityaMassachusetts General Hospital Cancer Center12
5Curigliano GiuseppeEuropean Institute of Oncology12
6Modi ShanuMemorial Sloan Kettering Cancer Center12
7Tsurutani JunjiShowa University11
8Iwata HirojiAichi Cancer Center Hospital10
9Tarantino PaoloDana-Farber Cancer Institute10
10Li WeiThe First Hospital of Jilin University10
11Schmid PeterQueen Mary University of London9
12Bianchini GiampaoloIRCCS Ospedale San Raffaele9
13Yan MinThe Affiliated Cancer Hospital of Zhengzhou University & H9
14Meric-Bernstam FundaThe University of Texas MD Anderson Cancer Center9
15Wildiers HansUniversity Hospitals Leuven8
16Pierga Jean-YvesUniversité Paris Cité8
17Wang XiaojiaZhejiang Cancer Hospital8
18Xu BingheCancer Hospital8

Ranked by recent publication volume; names not yet disambiguated and not citation-weighted. The full brief adds ORCID disambiguation, citation weighting, and clinical-trial investigator data.

Leading institutions

Memorial Sloan Kettering Cancer Center (27), Dana-Farber Cancer Institute (26), Inc. (23), AstraZeneca (22), Fudan University Shanghai Cancer Center (17), Seoul National University Hospital (16), University of Milan (16), Ltd. (15), University of Ulsan College of Medicine (15), Aichi Cancer Center Hospital (15)

Active subtopics

Immunoconjugates (387), Breast Neoplasms (358), Erb-b2 Receptor Tyrosine Kinases (347), Trastuzumab (268), Camptothecin (257), Antineoplastic Agents, Immunological (133), Antibodies, Monoclonal, Humanized (120), Neoplasm Metastasis (73), Antineoplastic Combined Chemotherapy Protocols (72)

Top journals

Frontiers in oncology (22), ESMO open (22), Cancers (14), Annals of oncology : official journal of the European Society for Medical Oncology (14), The oncologist (14), Future oncology (London, England) (11)

Representative recent papers

The human trophoblast cell-surface antigen 2 (TROP-2) expression on metastasized breast cancer. (2026) · PMID 42467304

HER2 Expression in Squamous Cell Carcinoma of the Vulva: A Systematic Review and Meta-Analysis. (2026) · PMID 42449705

Efficacy evaluation of novel targeted drugs in patients with human epidermal growth factor receptor 2-positive breast cancer: A me (2026) · PMID 42447291

A pneumolysin mutant (ΔA146 ply) induces pyroptosis in triple-negative and HER2-positive breast cancer cells via the Caspase-1/GSD (2026) · PMID 42445432

Duocarmycin-Bearing Antibody-Mimetic Drug Conjugate Combined With an ATR Inhibitor Results in Complete Tumor Regression in a KPL-4 (2026) · PMID 42410700

Want the full cited brief?

A full Breast Cancer brief adds citation weighting, name disambiguation, clinical-trial investigators, and a cited PDF, scoped to your exact molecule, competitor set, or region.

Try the live tool Contact us